BioStock: Cereno Scientific drives a paradigm shift in CVD

11 June 2021 - 12:26

Cardiovascular disease is the number one killer in the world, and conventional treatments are simply not enough. A review published in the Lancet Healthy Longevity last week describes the benefits of epigenetic modulation in treating some of the major pathophysiological mechanisms of cardiovascular disease, and how it opens up for new opportunities for within a broad spectrum of diseases, even beyond cardiovascular disease. In Sweden, biotech Cereno Scientific has already begun taking advantage of such opportunities and developed a strong drug development portfolio around epigenetic modulation. BioStock takes a closer look.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.

Provided by: Cision
Spotlight Stock Market (Sweden)
Cereno Scientific AB
Cereno Scientific are active within biotechnology. Today, the company is focused on developing pharmaceuticals for the treatment of various cardiovascular diseases. The products are used to treat potential blood clots that may lead to stroke, myocardial infarction, pulmonary embolism, as well as venous thrombosis....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More